美国头颈学会关于PD-1抑制剂用于晚期皮肤鳞状细胞癌治疗的立场声明
美国头颈学会(AHNS)制定循证立场声明,为PD-1抑制剂治疗晚期皮肤鳞状细胞癌提供推荐。通过文献检索和德尔菲法,26条声明达成共识,并指出免疫抑制对分期及PD-1抑制剂在免疫抑制患者中作用的知识空白。
要点
- 26条关于PD-1抑制剂治疗晚期皮肤鳞状细胞癌的立场声明达成共识。
- 知识空白包括免疫抑制对cSCC分期及治疗的影响。
- 知识空白包括PD-1抑制剂在免疫抑制患者中的作用。
核心结论
- 该立场声明代表全国执业头颈外科医生的多数共识。
研究设计与样本
- 美国头颈学会(AHNS)制定立场声明,通过文献检索(PubMed、Cochrane、Google Scholar)生成循证声明,并采用德尔菲法在领导团队中确定共识度≥70%的声明。
主要发现
- 26条立场声明达成共识。
- 未来研究的知识空白包括:免疫抑制对cSCC分期及相关治疗的影响;PD-1抑制剂在免疫抑制患者中的作用。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A position statement put forth by the American Head and Neck Society (AHNS) was constructed to provide evidence-based treatment recommendations for PD-1 inhibitor use in advanced cutaneous squamous cell carcinoma (cSCC). Secondarily, we sought to identify knowledge gaps warranting further investigation. METHODS: A literature search utilizing key terms: cutaneous squamous cell carcinoma, cutaneous cancer, checkpoint inhibitors, systemic therapy, Program Cell Death, PD-1 (PubMed, Cochrane, and Google Scholar) was carried out to generate evidence-based statements. The statements were distributed among the AHNS membership. Delphi methodology was applied to identify statements achieving 70% or greater consensus among the leadership team. RESULTS: Twenty-six position statements achieved consensus. Knowledge gaps for future research included: impact of immunosuppression on cSCC staging and associated treatment; role of PD-1 inhibitors in immunosuppressed patients. CONCLUSION: This comprehensive position statement put forth by the AHNS represents majority consensus by practicing head and neck surgeons throughout the country.
引用
- Schmalbach CE, Ow TJ, Choi KY, et al. American Head and Neck Society position statement on the use of PD-1 inhibitors for treatment of advanced cutaneous squamous cell carcinoma. Head Neck. 2022. PMID: 36181317. doi:10.1002/hed.27202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。